Immune thrombocytopenia is an immune disorder in which circulating antiplatelet antibodies sensitize platelets resulting in phagocytosis of this blood clotting element by the reticuloendothelial system.' Immune thrombocytopenia is an excellent human model to evaluate antigen, antibody (idiotype), and anti-idiotypic antibody interactions. With increasing interest in the study of anti-idiotypic antibodies and their role in the immune system network, it has become apparent that their development in certain immunologic situations may be associated with disease progression. This is the case in the experimental model of murine systemic lupus erythematosus (SLE) that can be induced by immunization with a human monoclonal anti-DNA antibody derived from an SLE patient expressing a common idiotype (designated 16/6 idiotype).2 In the present study, we investigated whether or not immune thrombocytopenic patients presenting with circulating antiplatelet antibodies also have corresponding antiidiotypic antibodies that may be associated with the disease process.
Two groups of immune thrombocytopenic patients were examined. The first group was patients having immune thrombocytopenic purpura with autoimmune production of antibody and the second group was patients having immune thrombocytopenia with alloimmune production of antibody and refractory to platelet transfusion. All patients were screened for the presence of circulating antiplatelet IgG antibody using a modification of a cellular enzyme-linked immunosorbent assay (ELISA) technique previously described. ' Of the patients testing positive in this assay system, 6 autoimmune and 10 alloimmune thrombocytopenic patients also tested positive for circulating anti-gpIIbIIIa IgG in an ELISA technique using platelet antigen gpIIbIIIa purified as previously de~cribed.~ IgG was purified from 2 to 4 mL of serum from each of the 6 autoimmune and each of the 10 alloimmune patients using protein A affinity chromatography. IgG F(ab'), fragments of each preparation were prepared by pepsin digestion. IgG F(ab'), idiotype fragments of each patient's autoantibody or alloantibody were then isolated by affinity chromatography using purified gpIIbIIIa platelet antigen immobilized on agarose. Each purified IgG F(ab'), preparation was then used as a target idiotype in an ELISA technique using a monoclonal antibody (Sigma Chemical CO, St Louis, MO) against the Fc portion of human
IgG as a detection system for IgG anti-idiotype. Pooled normal plasma from 30 donors was tested for reactivity against pooled normal IgG F(ab'), fragments and a normal reference value for nanograms of IgG per microliter was established by comparison against a standard curve of purified human IgG incubated in ELISA wells. Individual patient serum samples were assayed together with the normal donor plasma pool against their corresponding IgG F(ah')? idiotype to generate a value relative to the normal reference plasma value for nanograms of circulating IgG anti-idiotype per microliter of sample.
When tested for the presence of IgG anti-idiotype, the 6 autoimmune thrombocytopenic patients exhibited elevated levels of antiidiotypic activity (Fig 1) . In addition, the group of I O alloimmune thrombocytopenic patients exhibited elevated levels of anti-idiotypic activity (Fig 1) . The values for the 6 autoimmune and I O alloimmune patients were significantly ( P = ,0004 and P = ,002, respectively) elevated when compared with the values obtained from a group of 8 normal individual serum samples tested against each of the 16 IgG F(ab'), idiotype fragments (Fig l) . These data indicate that the immune thrombocytopenic patient population tested in this study had higher levels of anti-idiotypic antibody that appeared to be stimulated in response to the production of IgG autoantibody or alloantibody.
The data presented in this study suggest that anti-idiotypic activity is associated with the disease process in immune thrombocytopenia. If we assume that an original antigenic insult initiated the immune thrombocytopenia, it follows that there would be subsequent stimulation of an anti-idiotypic response, as proposed by Jeme. 5 The ensuing response in itself may exacerbate the immune process because of antigen mimicry of the anti-idiotypic antibody. This is exemplified in the murine model of SLE wherein clinical manifestations of the disease can be generated by immunization with anti-DNA antibody 16/6 idiotype., Indeed, after immunization and a single immunologic boost with 16/6 idiotype, mice produce anti-l6/6 idiotype antibodies, anti-DNA antibodies, and anti-nuclear antigen antibodies. Moreover, after a period of 4 to 6 months, the immunized mice developed proteinuria and leukopenia, and immune complexes were detected in their kidneys.' This experimental murine model closely parallels human SLE with respect to production of autoantibodies and suhse- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From quent clinical manifestations. Interestingly, a recent study by Mozes et al' proposed that failure to generate an idiotypic network may be protective for experimental murine SLE. If this model reflects an actual immune process in humans, then immune thrombocytopenic patients presenting with identifiable antiplatelet antibody should also exhibit corresponding anti-idiotypic antibody. This is indeed what we observed in the present study, which implicates the development of an anti-idiotypic response as an important factor associated with the immunopathology of immune thrombocytopenia. The observations reported here provide insight into the humoral immune processes that may contribute to immune thrombocytopenia.
